| Literature DB >> 20144313 |
Edward Abrahams1, Mike Silver.
Abstract
Personalized medicine may be considered an extension of traditional approaches to understanding and treating disease, but with greater precision. Physicians may now use a patient's genetic variation or expression profile as well as protein and metabolic markers to guide the selection of certain drugs or treatments. In many cases, the information provided by molecular markers predicts susceptibility to conditions. The added precision introduces the possibility of a more preventive, effective approach to clinical care and reductions in the duration and cost of clinical trials. Here, we make the case, through real-world examples, that personalized medicine is delivering significant value to individuals, to industry, and to the health care system overall and that it will continue to grow in importance if we can lift the barriers that impede its adoption and build incentives to encourage its practice. Copyright 2009 Diabetes Technology Society.Entities:
Mesh:
Year: 2009 PMID: 20144313 PMCID: PMC2769975 DOI: 10.1177/193229680900300411
Source DB: PubMed Journal: J Diabetes Sci Technol ISSN: 1932-2968